Add like
Add dislike
Add to saved papers

Concordance of Opioid Exposure in All Payers Claims Database with Prescription Drug Monitoring Program Database Using Arkansas as a Case Example.

Health Services Research 2022 December 16
OBJECTIVE: To assess the concordance between and benefit of adding prescription drug monitoring program (PDMP) data to all-payer claims database (APCD) data for identifying and classifying opioid exposure among insured individuals.

DATA SOURCES AND STUDY SETTING: Arkansas APCD and PDMP.

STUDY DESIGN: Enrollees in APCD were classified as 1) true positives: if they received opioids in both databases, 2) false positives: if they only received opioids in APCD, 3) true negatives: if they had no opioid exposure in both databases, 4) false negatives: if they only received opioids in the PDMP database. Specificity, sensitivity, negative, and positive predictive values were calculated using PDMP as the "gold standard" database source. Subjects were also categorized as those who received any opioid, chronic opioid, high dose opioid, or high-risk opioid therapies.

DATA COLLECTION/EXTRACTION METHODS: Arkansas residents continuously enrolled with pharmacy coverage in 2016 were included. APCD and PDMP were linked using an encrypted enrollee identifier, gender, and year of birth PRINCIPAL FINDINGS: The degree of concordance in opioid exposure between the two databases among 1,411,565 enrollees was high (sensitivity=92.67%, specificity=96.13%, positive predictive value=91.60%, negative predictive value=96.65%). Enrollees classified as having any opioid (APCD: 31.64% vs. PDMP: 31.26% vs. APCD+PDMP: 33.93%), chronic opioid (APCD: 7.81% vs. PDMP: 7.54% vs. APCD+PDMP: 8.24%), high dose opioid (APCD: 10.60% vs. PDMP: 9.62% vs. APCD+PDMP: 11.33%), or high-risk opioid (APCD: 5.28% vs. PDMP: 5.33% vs. APCD+PDMP: 6.20%) therapies, were similar using only APCD vs. PDMP vs. the combined APCD and PDMP data sources.

CONCLUSIONS: Claims data sources, such as APCDs, are fairly accurate in identifying opioid exposure and the level of opioid exposure among persons with continuous pharmacy coverage. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app